FDA Publishes Guidance on Drug Development for Male Breast Cancer
The agency provides recommendations for development and labeling of drugs to treat male patients with breast cancer.
FDA released guidance in August 2020 on the development and labeling of treatments for male patients with breast cancer. According to FDA, due to the rare nature of breast cancer in males, they have been excluded from clinical trials of breast cancer drugs.
The guidance recommends that both males and females should be included in eligibility criteria for clinical trials. “FDA does not intend to consider low expected accrual rates of male patients with breast cancer to be a sufficient scientific rationale for excluding them from a clinical trial,” the guidance states. In addition, the guidance states, “sponsors should conduct nonclinical general toxicology studies in male and female animals” when males are included in clinical trials for breast cancer treatments.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
